
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7240772/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Surveying Global Availability of Parkinson's Disease Treatment. Journal of Parkinson's Disease, 2022, 12, 1023-1034.	2.8	2
2	Sexual Dysfunction in Parkinson's Disease. , 2022, , 155-166.		1
3	Posttraumatic Stress Symptoms After Stroke: The Effects of Anatomy and Coping Style. Stroke, 2022, 53, 1924-1933.	2.0	7
4	Neuropathology of Non-Motor Parkinson's Disease Symptoms. , 2022, , 35-45.		0
5	Autonomic Dysfunction and Failure in Parkinson's Disease. , 2022, , 130-144.		0
6	Medical Cannabis for Gilles de la Tourette Syndrome: An Open-Label Prospective Study. Behavioural Neurology, 2022, 2022, 1-10.	2.1	4
7	Creutzfeldt-Jakob and Vascular Brain Diseases: Their Overlap and Relationships. Frontiers in Neurology, 2021, 12, 613991.	2.4	3
8	Can the RAVLT predict deterioration from MCI to dementia? Data from long term follow up. Experimental Aging Research, 2021, 47, 347-356.	1.2	5
9	The Interrelation Between Chronic Headache, Cognitive Scores, and MRI Markers Among Stroke Survivors. Journal of Alzheimer's Disease, 2021, 81, 1555-1566.	2.6	1
10	The assessment of cognitive and behavioural disturbances in vascular cognitive impairment (VCI) — recommendations of an expert working group. Neurologia I Neurochirurgia Polska, 2021, 55, 333-345.	1.2	3
11	The temporal and causal relationship between inflammation and neurodegeneration in multiple sclerosis. Multiple Sclerosis Journal, 2020, 26, 876-886.	3.0	41
12	Atypical duration of epileptic and psychogenic nonepileptic events. Epilepsy and Behavior, 2020, 111, 107145.	1.7	2
13	Familial Creutzfeldt–Jakob disease homozygous to the E200K mutation: clinical characteristics and disease course. Journal of Neurology, 2020, 267, 2455-2458.	3.6	8
14	Epilepsy subtype-specific copy number burden observed in a genome-wide study of 17 458 subjects. Brain, 2020, 143, 2106-2118.	7.6	47
15	Dementia in the COVID-19 Period. Journal of Alzheimer's Disease, 2020, 75, 1071-1072.	2.6	43
16	Management of mild cognitive impairment (MCI): The need for national and international guidelines. World Journal of Biological Psychiatry, 2020, 21, 579-594.	2.6	100
17	Ultra-Rare Genetic Variation in the Epilepsies: A Whole-Exome Sequencing Study of 17,606 Individuals. American Journal of Human Genetics, 2019, 105, 267-282.	6.2	237
18	Vascular and Neurodegenerative Markers for the Prediction of Post-Stroke Cognitive Impairment: Results from the TABASCO Study. Journal of Alzheimer's Disease, 2019, 70, 889-898.	2.6	33

#	Article	IF	CITATIONS
19	Quantitative analysis of phenotypic elements augments traditional electroclinical classification of common familial epilepsies. Epilepsia, 2019, 60, 2194-2203.	5.1	0
20	ApoE4: an emerging therapeutic target for Alzheimer's disease. BMC Medicine, 2019, 17, 64.	5.5	282
21	Translational research on reserve against neurodegenerative disease: consensus report of the International Conference on Cognitive Reserve in the Dementias and the Alzheimer's Association Reserve, Resilience and Protective Factors Professional Interest Area working groups. BMC Medicine, 2019. 17, 47.	5.5	69
22	Quality of life in Parkinson's disease: A genderâ€specific perspective. Acta Neurologica Scandinavica, 2019, 140, 17-22.	2.1	36
23	CCR5 Is a Therapeutic Target for Recovery after Stroke and Traumatic Brain Injury. Cell, 2019, 176, 1143-1157.e13.	28.9	249
24	Disease duration in E200K familial Creutzfeldt–Jakob disease is correlated with clinical, radiological, and laboratory variables. Journal of Neural Transmission, 2019, 126, 607-611.	2.8	9
25	An updated diagnostic approach to subtype definition of vascular parkinsonism – Recommendations from an expert working group. Parkinsonism and Related Disorders, 2018, 49, 9-16.	2.2	55
26	A Practical Measurement of Parkinson's Patients Gait Using Simple Walker-Based Motion Sensing and Data Analysis. Journal of Medical Devices, Transactions of the ASME, 2018, 12, .	0.7	7
27	Are dementia with Lewy bodies and Parkinson's disease dementia the same disease?. BMC Medicine, 2018, 16, 34.	5.5	232
28	Subtype definition of vascular parkinsonism. Parkinsonism and Related Disorders, 2018, 52, 107-108.	2.2	1
29	The Role of Sex Therapy in the Management of Patients with Parkinson's Disease. Movement Disorders Clinical Practice, 2018, 5, 6-13.	1.5	20
30	A critical review of the prion hypothesis of human synucleinopathies. Cell and Tissue Research, 2018, 373, 213-220.	2.9	30
31	The Price of Stress: High Bedtime Salivary Cortisol Levels Are Associated with Brain Atrophy and Cognitive Decline in Stroke Survivors. Results from the TABASCO Prospective Cohort Study. Journal of Alzheimer's Disease, 2018, 65, 1365-1375.	2.6	17
32	Clinical and radiological determinants of transient symptoms associated with infarction (TSI). Journal of the Neurological Sciences, 2018, 390, 195-199.	0.6	7
33	Post-stroke dementia $\hat{a} \in \hat{a}$ a comprehensive review. BMC Medicine, 2017, 15, 11.	5.5	442
34	Quality-of-life perception by Parkinson's disease patients and caregivers. Acta Neurologica Scandinavica, 2017, 136, 151-154.	2.1	17
35	Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL) as a model of small vessel disease: update on clinical, diagnostic, and management aspects. BMC Medicine, 2017, 15, 41.	5.5	212
36	ARTEMIDA Trial (A Randomized Trial of Efficacy, 12 Months International Double-Blind Actovegin). Stroke, 2017, 48, 1262-1270.	2.0	71

#	Article	IF	CITATIONS
37	Gait instability in valproate-treated patients: Call to measure ammonia levels. Acta Neurologica Scandinavica, 2017, 136, 401-406.	2.1	6
38	Only White Matter Hyperintensities Predicts Post-Stroke Cognitive Performances Among Cerebral Small Vessel Disease Markers: Results from the TABASCO Study. Journal of Alzheimer's Disease, 2017, 56, 1293-1299.	2.6	46
39	High hair cortisol concentrations predict worse cognitive outcome after stroke: Results from the TABASCO prospective cohort study. Psychoneuroendocrinology, 2017, 82, 133-139.	2.7	31
40	Myoclonus epilepsy and ataxia due to <scp><i>KCNC</i></scp> <i>1</i> mutation: Analysis of 20 cases and <scp>K</scp> <sup>+</sup> channel properties. Annals of Neurology, 2017, 81, 677-689.	5.3	69
41	Medical Cannabis in Parkinson Disease: Real-Life Patients' Experience. Clinical Neuropharmacology, 2017, 40, 268-272.	0.7	57
42	Genetic epilepsy with febrile seizures plus. Neurology, 2017, 89, 1210-1219.	1.1	112
43	The diabetic brain and cognition. Journal of Neural Transmission, 2017, 124, 1431-1454.	2.8	77
44	Type 2 Diabetes Mellitus and Impaired Renal Function Are Associated With Brain Alterations and Poststroke Cognitive Decline. Stroke, 2017, 48, 2368-2374.	2.0	43
45	Towards the concept of disease-modifier in post-stroke or vascular cognitive impairment: a consensus report. BMC Medicine, 2017, 15, 107.	5.5	77
46	Can Biomarkers Help the Early Diagnosis of Parkinson's Disease?. Neuroscience Bulletin, 2017, 33, 535-542.	2.9	42
47	Vascular Parkinsonism. , 2017, , 233-247.		0
48	The Lived Experience of Parkinson's Disease: A Content Analysis of Parkinson's Patients' Blogs. Israel Medical Association Journal, 2017, 19, 685-690.	0.1	6
49	CSF tau correlates with CJD disease severity and cognitive decline. Acta Neurologica Scandinavica, 2016, 133, 119-123.	2.1	25
50	Seizures as presenting and prominent symptom in choreaâ€acanthocytosis with c.2343del <i><scp>VPS</scp>13A</i> gene mutation. Epilepsia, 2016, 57, 549-556.	5.1	16
51	The effect of schooling on reported age of onset of cognitive decline: A collaborative study. Journal of Clinical Neuroscience, 2016, 34, 86-88.	1.5	3
52	Clinical radiological correlation in E200K familial Creutzfeldt–Jakob disease. Journal of Neural Transmission, 2016, 123, 1457-1462.	2.8	3
53	CSF tau correlates with the degree of cortical involvement in E200K familial Creutzfeldt-Jakob disease. Neuroscience Letters, 2016, 634, 76-78.	2.1	4
54	What is new in vascular dementia?. BMC Medicine, 2016, 14, 175.	5.5	6

#	Article	IF	CITATIONS
55	Cognitive state following mild stroke: A matter of hippocampal mean diffusivity. Hippocampus, 2016, 26, 161-169.	1.9	17
56	Unusual presentations in patients with E200K familial Creutzfeldtâ^'Jakob disease. European Journal of Neurology, 2016, 23, 871-877.	3.3	14
57	Multiplex families with epilepsy. Neurology, 2016, 86, 713-722.	1.1	23
58	Parkinson's and Alzheimer's diseases: Focus on mild cognitive impairment. Parkinsonism and Related Disorders, 2016, 22, S159-S161.	2.2	10
59	Consensus statement for diagnosis of subcortical small vessel disease. Journal of Cerebral Blood Flow and Metabolism, 2016, 36, 6-25.	4.3	173
60	Depressive Symptoms Following Stroke and Transient Ischemic Attack. Journal of Clinical Psychiatry, 2016, 77, 673-680.	2.2	15
61	Abstract TP460: Dominant Imaging Markers for Post Stroke Cognitive Performance in the TABASCO Study. Stroke, 2016, 47, .	2.0	О
62	Can the disease course in Parkinson's disease be slowed?. BMC Medicine, 2015, 13, 295.	5.5	15
63	What are the correlates of cognition and participation to return to work after first ever mild stroke?. Topics in Stroke Rehabilitation, 2015, 22, 317-325.	1.9	87
64	Familial neonatal seizures in 36 families: Clinical and genetic features correlate with outcome. Epilepsia, 2015, 56, 1071-1080.	5.1	94
65	Disorders of the Oral Cavity in Parkinson's Disease and Parkinsonian Syndromes. Parkinson's Disease, 2015, 2015, 1-6.	1.1	50
66	Mutation of the nuclear lamin gene <i>LMNB2</i> in progressive myoclonus epilepsy with early ataxia. Human Molecular Genetics, 2015, 24, 4483-4490.	2.9	41
67	Familial Creutzfeldt–Jakob disease with the E200K mutation: longitudinal neuroimaging from asymptomatic to symptomatic CJD. Journal of Neurology, 2015, 262, 604-613.	3.6	18
68	Life Style and the Prevention of Dementia. Neuroepidemiology, 2015, 44, 83-84.	2.3	2
69	Impact of first-ever mild stroke on participation at 3 and 6 month post-event: the TABASCO study. Disability and Rehabilitation, 2015, 37, 667-673.	1.8	67
70	Vascular parkinsonism—characteristics, pathogenesis and treatment. Nature Reviews Neurology, 2015, 11, 319-326.	10.1	113
71	Characterization of sleep disorders in patients with E200K familial Creutzfeldt–Jakob disease. Journal of Neurology, 2015, 262, 443-450.	3.6	9
72	Gait Measures as Predictors of Poststroke Cognitive Function. Stroke, 2015, 46, 1077-1083.	2.0	21

#	Article	IF	CITATIONS
73	Neuroprotection in ischemic stroke: what does the future hold?. Expert Review of Neurotherapeutics, 2015, 15, 227-229.	2.8	14
74	Third International Congress on Epilepsy, Brain, and Mind: Part 2. Epilepsy and Behavior, 2015, 50, 138-159.	1.7	8
75	Third International Congress on Epilepsy, Brain and Mind: Part 1. Epilepsy and Behavior, 2015, 50, 116-137.	1.7	13
76	International Congress on Vascular Dementia, Athens, Greece, 17–20 October 2013. Journal of Alzheimer's Disease, 2014, 42, S1-S1.	2.6	0
77	Mental Dysfunction in Parkinson's Disease. Journal of Parkinson's Disease, 2014, 4, 129-129.	2.8	Ο
78	Broad Phenotypic Heterogeneity due to a Novel <i>SCN1A</i> Mutation in a Family With Genetic Epilepsy With Febrile Seizures Plus. Journal of Child Neurology, 2014, 29, 221-226.	1.4	48
79	Diabetes and the brain: issues and unmet needs. Neurological Sciences, 2014, 35, 995-1001.	1.9	44
80	Nonsteroidal anti-inflammatory drugs exposure and the central nervous system. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2014, 119, 577-584.	1.8	90
81	Phosphatidylserine Containing Omega-3 Fatty Acids May Improve Memory Abilities in Nondemented Elderly Individuals with Memory Complaints: Results from an Open-Label Extension Study. Dementia and Geriatric Cognitive Disorders, 2014, 38, 39-45.	1.5	30
82	Sequence Variants in SLC6A3, DRD2, and BDNF Genes and Time to Levodopa-Induced Dyskinesias in Parkinson's Disease. Journal of Molecular Neuroscience, 2014, 53, 183-188.	2.3	67
83	Cognitive State following Stroke: The Predominant Role of Preexisting White Matter Lesions. PLoS ONE, 2014, 9, e105461.	2.5	38
84	ls Alzheimer's disease a homogeneous disease entity?. Journal of Neural Transmission, 2013, 120, 1475-1477.	2.8	6
85	JNT Special Issue MDPD Congress, Berlin 2012. Journal of Neural Transmission, 2013, 120, 507-507.	2.8	0
86	Mild cognitive impairment in Parkinson's disease. Journal of Neural Transmission, 2013, 120, 517-521.	2.8	14
87	Cognitive Assessment in Proximity to Acute Ischemic Stroke/Transient Ischemic Attack: Comparison of the Montreal Cognitive Assessment Test and MindStreams Computerized Cognitive Assessment Battery. Dementia and Geriatric Cognitive Disorders, 2013, 36, 36-42.	1.5	14
88	Editorial Comments: Is multiple sclerosis a neurodegenerative or inflammatory disease?. Journal of Neural Transmission, 2013, 120, 1457-1457.	2.8	1
89	Gender differences in lay persons' beliefs and knowledge about Alzheimer's disease (AD): A national representative study of Israeli adults. Archives of Gerontology and Geriatrics, 2013, 56, 400-404.	3.0	50
90	TBC1D24 mutation associated with focal epilepsy, cognitive impairment and a distinctive cerebro-cerebellar malformation. Epilepsy Research, 2013, 105, 240-244.	1.6	28

#	Article	IF	CITATIONS
91	Epilepsy, cognition, and neuropsychiatry (Epilepsy, Brain, and Mind, part 2). Epilepsy and Behavior, 2013, 28, 283-302.	1.7	55
92	Epilepsy, behavior, and art (Epilepsy, Brain, and Mind, part 1). Epilepsy and Behavior, 2013, 28, 261-282.	1.7	19
93	Targeted resequencing in epileptic encephalopathies identifies de novo mutations in CHD2 and SYNGAP1. Nature Genetics, 2013, 45, 825-830.	21.4	589
94	Elevated titers of anti-thyroperoxidase antibodies in patients with multiple system atrophy: A pilot study. Clinical Neurology and Neurosurgery, 2013, 115, 2348-2350.	1.4	2
95	Cognitive Decline After Stroke. Stroke, 2013, 44, 1433-1435.	2.0	77
96	Nonarteritic Ischemic Optic Neuropathy and Other Vascular Diseases. Neuroepidemiology, 2013, 40, 225-226.	2.3	4
97	Acquired Oculomotor Nerve Paresis with Cyclic Spasms in a Young Woman, a Rare Subtype of Neuromyotonia. Journal of Neuro-Ophthalmology, 2013, 33, 247-248.	0.8	11
98	Immunohistochemical analysis of sympathetic involvement in the SOD1-G93A transgenic mouse model of amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2013, 14, 424-433.	1.7	13
99	A Randomised, Double-Blind, Placebo-Controlled Trial of Actovegin in Patients with Post-Stroke Cognitive Impairment: ARTEMIDA Study Design. Dementia and Geriatric Cognitive Disorders Extra, 2013, 3, 459-467.	1.3	64
100	Subjective memory complaints in elders: depression, anxiety, or cognitive decline?. Acta Neurologica Scandinavica, 2013, 127, 344-350.	2.1	222
101	Gastric Dysfunction in Parkinson's Disease. , 2013, , 145-154.		2
102	The Use of Biomarkers for Prediction and Prevention of Alzheimer's and Parkinson's Diseases. Advances in Predictive, Preventive and Personalised Medicine, 2013, , 95-140.	0.6	2
103	Willingness to Use Computerized Systems for the Diagnosis of Dementia. Alzheimer Disease and Associated Disorders, 2012, 26, 171-178.	1.3	18
104	Cerebral White Matter Disruption in Creutzfeldt-Jakob Disease. American Journal of Neuroradiology, 2012, 33, 1945-1950.	2.4	22
105	Benign Neonatal Sleep Myoclonus. Journal of Child Neurology, 2012, 27, 1260-1263.	1.4	10
106	Why have we Failed to Cure Alzheimer's Disease?. Journal of Alzheimer's Disease, 2012, 29, 275-282.	2.6	38
107	Missense mutations in the sodium-gated potassium channel gene KCNT1 cause severe autosomal dominant nocturnal frontal lobe epilepsy. Nature Genetics, 2012, 44, 1188-1190.	21.4	333
108	Modeling the Dementia Epidemic. CNS Neuroscience and Therapeutics, 2012, 18, 175-181.	3.9	9

#	Article	IF	CITATIONS
109	Editorial comment: is essential tremor a neurodegenerative disease?. Journal of Neural Transmission, 2012, 119, 1373-1373.	2.8	0
110	Blood pressure measurements in a transgenic SOD1-G93A mouse model of amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2012, 13, 509-513.	2.1	8
111	43 Why have we failed to cure Alzheimer's disease?. Neurobiology of Aging, 2012, 33, S19.	3.1	2
112	Dyskinesias in patients with Parkinson's disease: Effect of the leucine-rich repeat kinase 2 (LRRK2) G2019S mutation. Parkinsonism and Related Disorders, 2012, 18, 1039-1041.	2.2	31
113	Occurrence of fatigue over 20 years after recovery from Guillain–Barré syndrome. Journal of the Neurological Sciences, 2012, 316, 72-75.	0.6	21
114	Neuroprotection in vascular dementia: A future path. Journal of the Neurological Sciences, 2012, 322, 232-236.	0.6	33
115	Microembolism, silent brain infarcts and dementia. Journal of the Neurological Sciences, 2012, 322, 250-253.	0.6	55
116	Vascular dementia. Journal of the Neurological Sciences, 2012, 322, 2-10.	0.6	131
117	Cerebral amyloid angiopathy impact on endothelium. Experimental Gerontology, 2012, 47, 838-842.	2.8	40
118	PRRT2 Mutations Cause Benign Familial Infantile Epilepsy and Infantile Convulsions with Choreoathetosis Syndrome. American Journal of Human Genetics, 2012, 90, 152-160.	6.2	234
119	Predictors for Poststroke Outcomes: The Tel Aviv Brain Acute Stroke Cohort (TABASCO) Study Protocol. International Journal of Stroke, 2012, 7, 341-347.	5.9	47
120	Vasomotor reactivity as a predictor for syncope in patients with orthostatism. Acta Neurologica Scandinavica, 2012, 126, 32-36.	2.1	8
121	Characterization of movement disorders in patients with familial Creutzfeldt-Jakob disease carrying the E200K mutation. Israel Medical Association Journal, 2012, 14, 162-5.	0.1	6
122	Efficacy and safety of a onceâ€daily formulation of Ginkgo biloba extract EGb 761 in dementia with neuropsychiatric features: a randomized controlled trial. International Journal of Geriatric Psychiatry, 2011, 26, 1186-1194.	2.7	96
123	Is there a need to redefine Parkinson's disease?. Journal of the Neurological Sciences, 2011, 310, 2-3.	0.6	3
124	Preface. Journal of the Neurological Sciences, 2011, 310, 1.	0.6	2
125	Retinal thickness in patients with mild cognitive impairment and Alzheimer's disease. Clinical Neurology and Neurosurgery, 2011, 113, 523-526.	1.4	247
126	Autonomic impairment in a transgenic mouse model of amyotrophic lateral sclerosis. Autonomic Neuroscience: Basic and Clinical, 2011, 159, 84-89.	2.8	21

#	Article	IF	CITATIONS
127	Antiphospholipid syndrome induction exacerbates a transgenic Alzheimer disease model on a female background. Neurobiology of Aging, 2011, 32, 272-279.	3.1	17
128	Commentary on "Recommendations from the National Institute on Agingâ€Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.― Alzheimer's and Dementia, 2011, 7, 333-334.	0.8	20
129	Current conceptions of the etiology and risk factors for Alzheimer's disease and their possible implications on the design of dementia clinical trials. Clinical Investigation, 2011, 1, 1491-1503.	0.0	0
130	Is amnestic mild cognitive impairment a useful concept?. Aging Health, 2011, 7, 107-122.	0.3	12
131	The role of apolipoprotein E polymorphisms in levodopa-induced dyskinesia. Acta Neurologica Scandinavica, 2011, 123, 117-121.	2.1	16
132	Sexual function in multiple sclerosis. Acta Neurologica Scandinavica, 2011, 124, 70-70.	2.1	0
133	The Creutzfeldt-Jakob disease (CJD) neurological status scale: a new tool for evaluation of disease severity and progression. Acta Neurologica Scandinavica, 2011, 124, 368-374.	2.1	14
134	Insulin resistance in tetraplegia but not in mid-thoracic paraplegia: is the mid-thoracic spinal cord involved in glucose regulation?. Spinal Cord, 2011, 49, 648-652.	1.9	9
135	Hemodynamic responses to head-up tilt after spinal cord injury support a role for the mid-thoracic spinal cord in cardiovascular regulation. Spinal Cord, 2011, 49, 251-256.	1.9	10
136	Pruritus in familial Creutzfeldt–Jakob disease: a common symptom associated with central nervous system pathology. Journal of Neurology, 2011, 258, 89-95.	3.6	29
137	Tau and 14-3-3 of genetic and sporadic Creutzfeldt–Jakob disease patients in Israel. Journal of Neurology, 2011, 258, 255-262.	3.6	32
138	Gender effect on time to levodopa-induced dyskinesias. Journal of Neurology, 2011, 258, 2048-2053.	3.6	50
139	CONy: a new perspective for readers of JNT. Journal of Neural Transmission, 2011, 118, 179-179.	2.8	Ο
140	Editorial comments. Journal of Neural Transmission, 2011, 118, 605-605.	2.8	0
141	Asymptomatic carotid artery stenosis (ACAS). Journal of Neural Transmission, 2011, 118, 629-629.	2.8	2
142	Editorial comments: treatment of motor fluctuations in Parkinson's disease. Journal of Neural Transmission, 2011, 118, 905-906.	2.8	0
143	Comment: should we diagnose MCI in Parkinson disease?. Journal of Neural Transmission, 2011, 118, 1177-1177.	2.8	5
144	AD: Are we intervening too late?. Journal of Neural Transmission, 2011, 118, 1359-1359.	2.8	1

#	Article	IF	CITATIONS
145	Safety of phosphatidylserine containing omega-3 fatty acids in non-demented elderly: a double-blind placebo-controlled trial followed by an open-label extension. BMC Neurology, 2011, 11, 79.	1.8	11
146	Computer-Based, Personalized Cognitive Training versus Classical Computer Games: A Randomized Double-Blind Prospective Trial of Cognitive Stimulation. Neuroepidemiology, 2011, 36, 91-99.	2.3	158
147	Smoking and amyotrophic lateral sclerosis. Annals of Neurology, 2010, 67, 694-694.	5.3	1
148	Biomarkers for prediction and targeted prevention of Alzheimer's and Parkinson's diseases: evaluation of drug clinical efficacy. EPMA Journal, 2010, 1, 273-292.	6.1	28
149	Mild adolescent/adult onset epilepsy and paroxysmal exerciseâ€induced dyskinesia due to GLUT1 deficiency. Epilepsia, 2010, 51, 2466-2469.	5.1	22
150	Prefrontal Compensatory Mechanism May Enable Normal Semantic Memory Performance in Mild Cognitive Impairment (MCI). Journal of Neuroimaging, 2010, 20, 163-168.	2.0	41
151	Female sexuality in multiple sclerosis: the multidimensional nature of the problem and the intervention. Acta Neurologica Scandinavica, 2010, 121, 289-301.	2.1	109
152	Cerebral vasomotor reactivity and dementia after ischemic stroke. Acta Neurologica Scandinavica, 2010, 122, 383-388.	2.1	7
153	Phosphatidylserine Containing ï‰â€"3 Fatty Acids May Improve Memory Abilities in Non-Demented Elderly with Memory Complaints: A Double-Blind Placebo-Controlled Trial. Dementia and Geriatric Cognitive Disorders, 2010, 29, 467-474.	1.5	81
154	Vascular Contribution to Dementia in Parkinson's Disease. Neurodegenerative Diseases, 2010, 7, 127-130.	1.4	10
155	Sick patient, normal tests. QJM - Monthly Journal of the Association of Physicians, 2010, 103, 117-119.	0.5	Ο
156	Delayed Start, Rapid Solution?. Neuroepidemiology, 2010, 35, 214-214.	2.3	2
157	Parkinson's disease: Before the motor symptoms and beyond. Journal of the Neurological Sciences, 2010, 289, 2-6.	0.6	31
158	Preface to special issue on Mental Dysfunction in Parkinson's Disease. Journal of the Neurological Sciences, 2010, 289, 1.	0.6	4
159	Is vascular cognitive impairment a useful concept?. Journal of the Neurological Sciences, 2010, 299, 2-4.	0.6	7
160	Vascular dementia 2009. Journal of the Neurological Sciences, 2010, 299, 1.	0.6	1
161	Lay persons' beliefs and knowledge about Parkinson's disease: Prevalence and socio-demographic correlates. Parkinsonism and Related Disorders, 2010, 16, 415-417.	2.2	11
162	Placebo responses in randomized trials of antiepileptic drugs. Epilepsy and Behavior, 2010, 17, 64-69.	1.7	39

#	Article	IF	CITATIONS
163	Teaching Sessions. Neuroepidemiology, 2009, 33, 305-316.	2.3	0
164	Practice parameters and technology assessments: What they are, what they are not, and why you should care. Neurology, 2009, 73, 1336-1337.	1.1	87
165	Can Treatment With Nonsteroidal Anti-inflammatory Drugs Protect From Dementia?. Archives of Neurology, 2009, 66, 538.	4.5	11
166	Use of the Virtual Action Planning Supermarket for the Diagnosis of Mild Cognitive Impairment. Dementia and Geriatric Cognitive Disorders, 2009, 27, 301-309.	1.5	100
167	Thalamo-striatal diffusion reductions precede disease onset in prion mutation carriers. Brain, 2009, 132, 2680-2687.	7.6	32
168	5-hydroxytryptamine in platelets of torsion dystonia patients. Acta Neurologica Scandinavica, 2009, 71, 171-173.	2.1	2
169	Biomarkers for Evaluation of Clinical Efficacy of Multipotential Neuroprotective Drugs for Alzheimer's and Parkinson's Diseases. Neurotherapeutics, 2009, 6, 128-140.	4.4	23
170	Visual evoked potentials in idiopathic intracranial hypertension. Clinical Neurology and Neurosurgery, 2009, 111, 433-436.	1.4	30
171	Smoking and tea consumption delay onset of Parkinson's disease. Parkinsonism and Related Disorders, 2009, 15, 41-46.	2.2	80
172	Vascular dementia 2007. Journal of the Neurological Sciences, 2009, 283, 1.	0.6	2
173	Depression and dementia. Journal of the Neurological Sciences, 2009, 283, 139-142.	0.6	139
174	2nd World Congress on Controversies in Neurology. Expert Review of Neurotherapeutics, 2009, 9, 317-318.	2.8	0
175	Commentary on "A roadmap for the prevention of dementia II: Leon Thal Symposium 2008.―Comments from abroad. , 2009, 5, 157-158.		0
176	A roadmap for the prevention of dementia II: Leon Thal Symposium 2008. Alzheimer's and Dementia, 2009, 5, 85-92.	0.8	44
177	Early onset dementia: clinical and social aspects. International Psychogeriatrics, 2009, 21, 631-636.	1.0	94
178	Is dementia preventable?. Dialogues in Clinical Neuroscience, 2009, 11, 213-216.	3.7	9
179	A Homozygous Mutation in Human PRICKLE1 Causes an Autosomal-Recessive Progressive Myoclonus Epilepsy-Ataxia Syndrome. American Journal of Human Genetics, 2008, 83, 572-581.	6.2	199
180	Possible remote functional reorganization in left temporal lobe epilepsy. Acta Neurologica Scandinavica, 2008, 117, 324-331.	2.1	3

#	Article	IF	CITATIONS
181	Cold pressor test in tetraplegia and paraplegia suggests an independent role of the thoracic spinal cord in the hemodynamic responses to cold. Spinal Cord, 2008, 46, 33-38.	1.9	16
182	X-linked protocadherin 19 mutations cause female-limited epilepsy and cognitive impairment. Nature Genetics, 2008, 40, 776-781.	21.4	397
183	Occurrence of seizures in association with workâ€related stress in young male army recruits. Epilepsia, 2008, 49, 1451-1456.	5.1	38
184	The amyloid cascade hypothesis. Alzheimer's and Dementia, 2008, 4, 176-178.	0.8	98
185	Treatment of advanced Alzheimer's disease with cholinesterase inhibitors. , 2008, 4, 371-372.		1
186	Paroxysmal exercise-induced dyskinesia and epilepsy is due to mutations in SLC2A1, encoding the glucose transporter GLUT1. Brain, 2008, 131, 1831-1844.	7.6	340
187	Epilepsy and mental retardation limited to females: an under-recognized disorder. Brain, 2008, 131, 918-927.	7.6	172
188	Thrombin receptor PAR-1 on myelin at the node of Ranvier: a new anatomy and physiology of conduction block. Brain, 2008, 131, 1113-1122.	7.6	33
189	Mild cognitive impairment: Conceptual, assessment, ethical, and social issues. Clinical Interventions in Aging, 2008, Volume 3, 413-420.	2.9	69
190	Computerized Methods for Cognitive Testing. , 2008, , 203-215.		2
191	Drug Trials in Dementia: Challenging Ethical Dilemmas. Current Alzheimer Research, 2007, 4, 468-472.	1.4	4
192	Computerized Methods in the Assessment and Prediction of Dementia. Current Alzheimer Research, 2007, 4, 364-369.	1.4	23
193	Chapter 9 GM2 gangliosidoses. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2007, 82, 171-177.	1.8	0
194	Galantamine treatment of vascular dementia. Neurology, 2007, 69, 448-458.	1.1	167
195	Modified Cold Pressor Test by Cold Application to the Foot After Spinal Cord Injury. American Journal of Physical Medicine and Rehabilitation, 2007, 86, 875-882.	1.4	17
196	Late-life depression as a risk factor for dementia. Future Neurology, 2007, 2, 201-208.	0.5	6
197	Increased KPI containing amyloid precursor protein in experimental autoimmune encephalomyelitis brains. NeuroReport, 2007, 18, 581-584.	1.2	11
198	The effect of cigarette smoking, tea, and coffee consumption on the progression of Parkinson's disease. Parkinsonism and Related Disorders, 2007, 13, 243-245.	2.2	39

#	Article	IF	CITATIONS
199	Computerized diagnosis of mild cognitive impairment. , 2007, 3, 23-27.		17
200	Vascular parkinsonism. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2007, 84, 417-425.	1.8	9
201	Cerebral vasomotor reactivity of patients with acute ischemic stroke: Cortical versus subcortical infarcts: An Israeli–Turkish collaborative study. Journal of the Neurological Sciences, 2007, 257, 121-125.	0.6	15
202	High b-value diffusion imaging of dementia: Application to vascular dementia and alzheimer disease. Journal of the Neurological Sciences, 2007, 257, 105-113.	0.6	33
203	The prevention of the dementia epidemic. Journal of the Neurological Sciences, 2007, 257, 2-4.	0.6	64
204	Clinical diagnostic criteria for dementia associated with Parkinson's disease. Movement Disorders, 2007, 22, 1689-1707.	3.9	2,497
205	Rotigotine transdermal patch in early Parkinson's disease: A randomized, doubleâ€blind, controlled study versus placebo and ropinirole. Movement Disorders, 2007, 22, 2398-2404.	3.9	214
206	Tenâ€year followâ€up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa. Movement Disorders, 2007, 22, 2409-2417.	3.9	221
207	Diagnostic procedures for Parkinson's disease dementia: Recommendations from the movement disorder society task force. Movement Disorders, 2007, 22, 2314-2324.	3.9	885
208	Hemodynamic effects of liquid food ingestion in mid-thoracic paraplegia: is supine postprandial hypotension related to thoracic spinal cord damage?. Spinal Cord, 2007, 45, 96-103.	1.9	34
209	Founder Effect with Variable Age at Onset in Arab Families with Lafora Disease and EPM2A Mutation. Epilepsia, 2007, 48, 1011-1014.	5.1	22
210	Comments on the article by Mazza <i>et al.</i> concerning <i>Ginkgo biloba</i> and donepezil: a comparison in the treatment of Alzheimer's dementia in a randomized placeboâ€controlled doubleâ€blind study. European Journal of Neurology, 2007, 14, e9; author reply e10.	3.3	3
211	Mortality in Parkinson?s disease. Acta Neurologica Scandinavica, 2007, 115, 367-367.	2.1	0
212	Transdermal therapy in Parkinson's disease. Lancet Neurology, The, 2007, 6, 475-476.	10.2	5
213	Drugs for vascular dementia. Lancet Neurology, The, 2007, 6, 749-751.	10.2	6
214	Identification of Histidine-Rich Glycoprotein, a Potential Autoantigen, in Human and Rat Brain Preparations. Annals of the New York Academy of Sciences, 2007, 1109, 473-483.	3.8	11
215	Rotigotine transdermal system for perioperative administration. Journal of Neural Transmission, 2007, 114, 219-221.	2.8	32
216	Cerebral vasomotor reactivity in Parkinson's disease, multiple system atrophy and pure autonomic failure. Journal of the Neurological Sciences, 2006, 243, 57-60.	0.6	19

#	Article	IF	CITATIONS
217	Toxic exposure and Parkinson's disease. Journal of the Neurological Sciences, 2006, 247, 242.	0.6	Ο
218	Dementia in Parkinson's disease. Journal of the Neurological Sciences, 2006, 248, 1-2.	0.6	3
219	Management of sleep problems in Parkinson's disease. Journal of the Neurological Sciences, 2006, 248, 163-166.	0.6	21
220	Dementia with Lewy bodies. Journal of the Neurological Sciences, 2006, 248, 3-8.	0.6	10
221	Risk factors for Alzheimer's disease in Russia: a case–control study. European Journal of Neurology, 2006, 13, 990-995.	3.3	24
222	Apolipoprotein e4 advances appearance of psychosis in patients with Parkinson's disease. Acta Neurologica Scandinavica, 2006, 113, 14-17.	2.1	35
223	Effect of rivastigmine on tremor in patients with Parkinson's disease and dementia. Movement Disorders, 2006, 21, 1663-1666.	3.9	31
224	Development of dyskinesias in a 5â€year trial of ropinirole and <scp>L</scp> â€dopa. Movement Disorders, 2006, 21, 1844-1850.	3.9	145
225	Evoked potential studies in the antiphospholipid syndrome: differential diagnosis from multiple sclerosis. Annals of the Rheumatic Diseases, 2006, 65, 525-528.	0.9	10
226	Visual disturbances in Parkinson's disease. Practical Neurology, 2006, 6, 28-33.	1.1	8
227	Autonomic impairment in amyotrophic lateral sclerosis. Current Opinion in Neurology, 2005, 18, 487-493.	3.6	126
228	Incidence of dementia in patients with subjective memory complaints. International Psychogeriatrics, 2005, 17, 265-273.	1.0	46
229	White matter changes in multiple sclerosis: correlation of q-space diffusion MRI and 1H MRS. Magnetic Resonance Imaging, 2005, 23, 703-710.	1.8	60
230	Diagnosis and management of dementia with Lewy bodies. Neurology, 2005, 65, 1863-1872.	1.1	4,604
231	Inhibition of Ras attenuates the course of experimental autoimmune neuritis. Journal of Neuroimmunology, 2005, 168, 46-55.	2.3	20
232	Increased thrombin inhibition in experimental autoimmune encephalomyelitis. Journal of Neuroscience Research, 2005, 79, 351-359.	2.9	42
233	Gastric Dysfunction. , 2005, , 105-113.		1
234	Analysis of Genetic Polymorphisms in Acetylcholinesterase as Reflected in Different Populations. Current Alzheimer Research, 2005, 2, 207-218.	1.4	16

#	Article	IF	CITATIONS
235	Antiphospholipid Antibodies Bind ATP: A putative Mechanism for the Pathogenesis of Neuronal Dysfunction. Clinical and Developmental Immunology, 2005, 12, 175-180.	3.3	14
236	A new clinical and molecular form of Unverricht-Lundborg disease localized by homozygosity mapping. Brain, 2005, 128, 652-658.	7.6	45
237	Neuropsychological evaluation of late-onset post-radiotherapy encephalopathy: a comparison with vascular dementia. Journal of the Neurological Sciences, 2005, 229-230, 195-200.	0.6	46
238	Vascular dementia 2003. Journal of the Neurological Sciences, 2005, 229-230, 1-2.	0.6	1
239	The underdiagnosis of the vascular contribution to dementia. Journal of the Neurological Sciences, 2005, 229-230, 3-6.	0.6	36
240	Hidden function of neuronal nicotinic acetylcholine receptor β2 subunits in ganglionic transmission: comparison to α5 and β4 subunits. Journal of the Neurological Sciences, 2005, 228, 167-177.	0.6	8
241	Alzheimer's disease and vascular brain lesions. Journal of the Neurological Sciences, 2005, 231, 1-2.	0.6	5
242	MRI parameters of Alzheimer's disease in an Arab population of Wadi Ara, Israel. Neuropsychiatric Disease and Treatment, 2005, 1, 77-85.	2.2	1
243	Sexual Dysfunction in Parkinson's Disease. Journal of Sex and Marital Therapy, 2004, 30, 95-105.	1.5	160
244	Idiopathic intracranial hypertension. Neurology, 2004, 63, 1737-1739.	1.1	120
245	<i>LGI1</i> mutations in temporal lobe epilepsies. Neurology, 2004, 62, 1115-1119.	1.1	79
246	Ropinirole in Gilles de la Tourette syndrome. Neurology, 2004, 62, 1626-1627.	1.1	57
247	R-R interval variation in Parkinson's disease and multiple system atrophy. Acta Neurologica Scandinavica, 2004, 109, 276-279.	2.1	16
248	Subdivision of essential tremor patients according to physiologic characteristics. Acta Neurologica Scandinavica, 2004, 109, 393-397.	2.1	11
249	Genetic Architecture of Idiopathic Generalized Epilepsy: Clinical Genetic Analysis of 55 Multiplex Families. Epilepsia, 2004, 45, 467-478.	5.1	128
250	Human–computer interaction in the administration and analysis of neuropsychological tests. Computer Methods and Programs in Biomedicine, 2004, 73, 43-53.	4.7	21
251	Parkin mutation associated parkinsonism and cognitive decline, comparison to early onset Parkinson?s disease. Journal of Neural Transmission, 2004, 111, 47-57.	2.8	31
252	Antiparkinsonian medication is not a risk factor for the development of hallucinations in Parkinson?s disease. Journal of Neural Transmission, 2004, 111, 1447-1453.	2.8	100

#	Article	IF	CITATIONS
253	A paradigm for single nucleotide polymorphism analysis: The case of the acetylcholinesterase gene. Human Mutation, 2004, 24, 408-416.	2.5	25
254	Nicotinic acetylcholine receptor α5 subunits modulate oxotremorine-induced salivation and tremor. Journal of the Neurological Sciences, 2004, 222, 87-91.	0.6	10
255	Plasma homocysteine, vitamin B12 and folate in Alzheimer's patients and healthy Arabs in Israel. Journal of the Neurological Sciences, 2004, 227, 109-113.	0.6	38
256	P1-092 Human-computer interaction in the administration and analysis of neuropsychological tests — A follow-up study. Neurobiology of Aging, 2004, 25, S121.	3.1	0
257	Drug treatment of Parkinson's disease. Dialogues in Clinical Neuroscience, 2004, 6, 315-322.	3.7	22
258	Genetic and Environmental Epidemiology of Alzheimer's Disease in Arabs Residing in Israel. Journal of Molecular Neuroscience, 2003, 20, 207-212.	2.3	24
259	Epidemiology of dementia in Ashkelon. Journal of Neurology, 2003, 250, 424-428.	3.6	21
260	Hexosaminidase A deficiency is an uncommon cause of a syndrome mimicking amyotrophic lateral sclerosis. Muscle and Nerve, 2003, 28, 109-112.	2.2	27
261	Prevalence of myotonic dystrophy in Israeli Jewish communities: Inter-community variation and founder premutations. American Journal of Medical Genetics Part A, 2003, 119A, 273-278.	2.4	18
262	Effects of rivastigmine on the quantitative EEG in demented Parkinsonian patients. Acta Neurologica Scandinavica, 2003, 107, 252-255.	2.1	44
263	Rivastigmine (Exelon) for dementia in patients with Parkinson's disease. Acta Neurologica Scandinavica, 2003, 108, 368-373.	2.1	76
264	Cortical lesions associated with transient neurological symptoms - not always a matter of cause and effect. European Journal of Neurology, 2003, 10, 721-725.	3.3	1
265	Inhibition of ras by farnesylthiosalicylate significantly reduces the levels of autoantibodies in two animal models of the antiphospholipid syndrome. Immunobiology, 2003, 207, 47-50.	1.9	8
266	Generalized convulsive status epilepticus in Creutzfeldt–Jakob disease. Seizure: the Journal of the British Epilepsy Association, 2003, 12, 403-405.	2.0	27
267	Neuronal-binding antibodies from patients with antiphospholipid syndrome induce cognitive deficits following intrathecal passive transfer. Lupus, 2003, 12, 436-442.	1.6	119
268	Identification of multiple loci for Alzheimer disease in a consanguineous Israeli-Arab community. Human Molecular Genetics, 2003, 12, 415-422.	2.9	117
269	Deficiency of Nicotinic Acetylcholine Receptor β4 Subunit Causes Autonomic Cardiac and Intestinal Dysfunction. Molecular Pharmacology, 2003, 63, 574-580.	2.3	39
270	Oculopharyngeal Muscular Dystrophy. , 2003, , 662-665.		0

Oculopharyngeal Muscular Dystrophy., 2003, , 662-665. 270

#	Article	IF	CITATIONS
271	Dopaminergic drugs in development for Parkinson's disease. Advances in Neurology, 2003, 91, 267-71.	0.8	8
272	Stroke in Hospitalized Patients: Are There Special Risk Factors?. Cerebrovascular Diseases, 2002, 13, 127-131.	1.7	57
273	Behavioral and cognitive deficits occur only after prolonged exposure of mice to antiphospholipid antibodies. Lupus, 2002, 11, 736-743.	1.6	70
274	Homocysteine, Stroke, and Dementia. Stroke, 2002, 33, 2343-2344.	2.0	25
275	Recruitment for Drug Studies in Dementia. Alzheimer Disease and Associated Disorders, 2002, 16, 283-284.	1.3	4
276	Copolymer 1 (Glatiramer Acetate) in Relapsing Forms of Multiple Sclerosis: Open Multicenter Study of Alternate-Day Administration. Clinical Neuropharmacology, 2002, 25, 11-15.	0.7	11
277	The complex nosological concept of vascular dementia. Journal of the Neurological Sciences, 2002, 203-204, 3-6.	0.6	31
278	Vascular dementia among elderly Arabs in Wadi Ara. Journal of the Neurological Sciences, 2002, 203-204, 73-76.	0.6	26
279	Prevalence and clinical features of dementia associated with the antiphospholipid syndrome and circulating anticoagulants. Journal of the Neurological Sciences, 2002, 203-204, 81-84.	0.6	50
280	High b value q-space-analyzed diffusion MRI in vascular dementia: A preliminary study. Journal of the Neurological Sciences, 2002, 203-204, 235-239.	0.6	47
281	Emerging Therapies in the Pharmacological Treatment of Parkinson???s Disease. Drugs, 2002, 62, 775-786.	10.9	23
282	Hamilton Depression Scale in dementia. International Journal of Psychiatry in Clinical Practice, 2002, 6, 91-94.	2.4	11
283	Quality of sexual life in Parkinson's disease. Parkinsonism and Related Disorders, 2002, 8, 243-246.	2.2	68
284	The role of neuronal nicotinic acetylcholine receptor subunits in autonomic ganglia: lessons from knockout mice. Progress in Neurobiology, 2002, 68, 341-360.	5.7	72
285	Oral solution of levodopa ethylester for treatment of response fluctuations in patients with advanced Parkinson's disease. Movement Disorders, 2002, 17, 297-302.	3.9	33
286	Highb-valueq-space analyzed diffusion-weighted MRI: Application to multiple sclerosis. Magnetic Resonance in Medicine, 2002, 47, 115-126.	3.0	228
287	Changes in axonal morphology in experimental autoimmune neuritis as studied by highb-value q-space1H and2H DQF diffusion magnetic resonance spectroscopy. Magnetic Resonance in Medicine, 2002, 48, 71-81.	3.0	27
288	Assessment of experimental autoimmune neuritis in the rat by electrophysiology of the tail nerve. Muscle and Nerve, 2002, 25, 51-57.	2.2	17

#	Article	IF	CITATIONS
289	A pilot, randomized, open-label trial assessing safety and pharmakokinetic parameters of co-administration of rivastigmine with risperidone in dementia patients with behavioral disturbances. International Journal of Geriatric Psychiatry, 2002, 17, 343-346.	2.7	37
290	Genetic and environmental risk factors for alzheimer's disease in israeli arabs. Journal of Molecular Neuroscience, 2002, 19, 239-245.	2.3	42
291	A six-month multicentre, double-blind, bromocriptine-controlled study of the safety and efficacy of ropinirole in the treatment of patients with Parkinson's disease not optimally controlled by L-dopa. Journal of Neural Transmission, 2002, 109, 489-501.	2.8	53
292	Dosing with ropinirole in a clinical setting. Acta Neurologica Scandinavica, 2002, 106, 200-204.	2.1	15
293	Autonomic function in mice lacking α5 neuronal nicotinic acetylcholine receptor subunit. Journal of Physiology, 2002, 542, 347-354.	2.9	73
294	Mixed Dementia—the Most Common Cause of Dementia. Annals of the New York Academy of Sciences, 2002, 977, 129-134.	3.8	190
295	Reply to Possible Duplicate Publication. Journal of Clinical Psychopharmacology, 2002, 22, 233.	1.4	0
296	Autonomic dysfunction in experimental autoimmune neuritis:. Journal of the Neurological Sciences, 2001, 184, 183-188.	0.6	4
297	Association of APOE ε4 allele with survival in amyotrophic lateral sclerosis. Journal of the Neurological Sciences, 2001, 190, 17-20.	0.6	87
298	The value of muscle exercise in patients with amyotrophic lateral sclerosis. Journal of the Neurological Sciences, 2001, 191, 133-137.	0.6	242
299	Hallucinations in Parkinson's disease. Lancet, The, 2001, 358, 1031-1032.	13.7	29
300	West Nile Encephalitis in Israel, 1999: The New York Connection. Emerging Infectious Diseases, 2001, 7, 659-661.	4.3	49
301	Precipitation of Hereditary Motor–Sensory Neuropathy Following Hepatitis B Vaccination. Journal of Clinical Neuromuscular Disease, 2001, 3, 75-76.	0.7	3
302	The Use of Intravenous Immunoglobulin as Maintenance Therapy in Myasthenia Gravis. Clinical Neuropharmacology, 2001, 24, 173-176.	0.7	42
303	Quantitative measurements of mouse brain thrombin-like and thrombin inhibition activities. NeuroReport, 2001, 12, 2347-2351.	1.2	26
304	The effects of <i>APOE</i> genotype on age at onset and progression of neurodegenerative diseases. Neurology, 2001, 57, 1482-1485.	1.1	65
305	Antibodies to brain antigens following stroke. Neurology, 2001, 56, 529-530.	1.1	90
306	Clinical characteristics of neuroleptic-induced parkinsonism. Journal of Neural Transmission, 2001, 108, 1299-1308.	2.8	67

#	Article	IF	CITATIONS
307	EEG changes during long-term treatment with donepezil in Alzheimer's disease patients. Journal of Neural Transmission, 2001, 108, 1167-1173.	2.8	53
308	Freezing of gait in patients with advanced Parkinson's disease. Journal of Neural Transmission, 2001, 108, 53-61.	2.8	338
309	Tolerance to the analgesic effect of buprenorphine, butorphanol, nalbuphine, and cyclorphan, and cross-tolerance to morphine. Journal of Anesthesia, 2001, 15, 204-209.	1.7	14
310	Treatment of MRL/lpr mice, a genetic autoimmune model, with the Ras inhibitor, farnesylthiosalicylate (FTS). Clinical and Experimental Immunology, 2001, 126, 570-577.	2.6	42
311	A History of Migraine Is Not A Risk Factor to Develop an Ischemic Stroke in the Elderly. Headache, 2001, 41, 399-401.	3.9	57
312	Prevalence of Alzheimer's type dementia in an elderly Arab population. European Journal of Neurology, 2001, 8, 119-123.	3.3	65
313	The assessment of radiating low back pain by thermal sensory testing. European Journal of Pain, 2001, 5, 347-351.	2.8	16
314	Quantitative anal sphincter EMG in multisystem atrophy and 100 controls. Journal of Neurology, Neurosurgery and Psychiatry, 2001, 71, 596-599.	1.9	38
315	The nigrostriatal dopaminergic system in familial early onset parkinsonism with <i>parkin</i> mutations. Neurology, 2001, 56, 1759-1762.	1.1	54
316	<i>APOE</i> genotype is a major predictor of long-term progression of disability in MS. Neurology, 2001, 56, 312-316.	1.1	162
317	Hyperactivity in a mouse model of the antiphospholipid syndrome. Lupus, 2001, 10, 496-499.	1.6	63
318	Unverricht–Lundborg disease in a five-generation Arab family. Neurology, 2001, 57, 1050-1054.	1.1	20
319	Mental and Motor Switching in Parkinson's Disease. Journal of Motor Behavior, 2001, 33, 377-385.	0.9	29
320	Treating Tardive Dyskinesia With Ondansetron. Journal of Clinical Psychopharmacology, 2001, 21, 355-356.	1.4	8
321	Dr. Sirota and Colleagues Reply. American Journal of Psychiatry, 2001, 158, 658-658.	7.2	1
322	Use of the Selective Serotonin 3 Receptor Antagonist Ondansetron in the Treatment of Neuroleptic-Induced Tardive Dyskinesia. American Journal of Psychiatry, 2000, 157, 287-289.	7.2	74
323	Recruitment Rate to Drug Trials for Dementia of the Alzheimer Type. Alzheimer Disease and Associated Disorders, 2000, 14, 209-211.	1.3	31
324	Rasagiline Mesylate, a New Mao-B Inhibitor for the Treatment of Parkinson's Disease: A Double-Blind Study as Adjunctive Therapy to Levodopa. Clinical Neuropharmacology, 2000, 23, 324-330.	0.7	153

#	Article	IF	CITATIONS
325	Demented patients' participation in a clinical trial: factors affecting the caregivers' decision. , 2000, 15, 325-330.		21
326	The diagnostic aid of routine EEG findings in patients presenting with a presumed first-ever unprovoked seizure. Epilepsy Research, 2000, 42, 197-202.	1.6	37
327	Risk factors for dementia, depression and psychosis in long-standing Parkinson's disease. Journal of Neural Transmission, 2000, 107, 59-71.	2.8	197
328	An open trial of amantadine and buspirone for cerebellar ataxia: a disappointment. Journal of Neural Transmission, 2000, 107, 1187-1189.	2.8	16
329	Dementia and Antiphospholipid Antibodies. Dementia and Geriatric Cognitive Disorders, 2000, 11, 36-38.	1.5	61
330	Muscarinic M1 agonists in the treatment of Alzheimer's disease. Expert Opinion on Investigational Drugs, 2000, 9, 2259-2267.	4.1	30
331	Oculopharyngeal MD among Bukhara Jews is due to a founder (GCG)9 mutation in the PABP2 gene. Neurology, 2000, 55, 1267-1270.	1.1	45
332	Sound lateralization and interaural discrimination Hearing Research, 2000, 143, 29-42.	2.0	58
333	Physically traumatic events in patients with epilepsy compared with non-epileptic subjects. Seizure: the Journal of the British Epilepsy Association, 2000, 9, 595-597.	2.0	12
334	Construction of freezing of gait questionnaire for patients with Parkinsonism. Parkinsonism and Related Disorders, 2000, 6, 165-170.	2.2	669
335	A Five-Year Study of the Incidence of Dyskinesia in Patients with Early Parkinson's Disease Who Were Treated with Ropinirole or Levodopa. New England Journal of Medicine, 2000, 342, 1484-1491.	27.0	1,467
336	Re: The Apolipoprotein E ε4 Allele Increases the Risk of Drug-Induced Hallucinations in Parkinson's Disease. Clinical Neuropharmacology, 2000, 23, 230-231.	0.7	6
337	Preliminary Observations on APOE ϵ4 Allele and Progression of Disability in Multiple Sclerosis. Archives of Neurology, 1999, 56, 1484.	4.5	47
338	Antiphospholipid antibodies permeabilize and depolarize brain synaptoneurosomes. Lupus, 1999, 8, 127-133.	1.6	181
339	Quality of life in Alzheimer's disease. European Journal of Neurology, 1999, 6, 487-489.	3.3	7
340	Postmeningitis Headache. Headache, 1999, 39, 132-134.	3.9	19
341	Fasting Headache, Weight Loss, and Dehydration. Headache, 1999, 39, 225-227.	3.9	44
342	Life-long history of injuries related to seizures. Epilepsy Research, 1999, 34, 123-127.	1.6	118

#	Article	IF	CITATIONS
343	Homozygotes for oculopharyngeal muscular dystrophy have a severe form of the disease. Annals of Neurology, 1999, 46, 115-118.	5.3	92
344	Zolmitriptan Provides Consistent Migraine Relief when Used in the Long Term. Current Medical Research and Opinion, 1999, 15, 272-281.	1.9	22
345	Ancestral Origins and Worldwide Distribution of the PRNP 200K Mutation Causing Familial Creutzfeldt-Jakob Disease. American Journal of Human Genetics, 1999, 64, 1063-1070.	6.2	85
346	Intermittent rhythmic delta activity (IRDA) morphology cannot distinguish between focal and diffuse brain disturbances. Journal of the Neurological Sciences, 1999, 164, 56-59.	0.6	14
347	Denbufylline in Dementia: A Double-Blind Controlled Study. Dementia and Geriatric Cognitive Disorders, 1999, 10, 505-510.	1.5	21
348	Penetrance and Phenotypic Expression of a Mutation Linked to Creutzfeldt-Jakob Disease in the Elderly. Dementia and Geriatric Cognitive Disorders, 1999, 10, 47-50.	1.5	3
349	The A677V Methylenetetrahydrofolate Reductase Gene Polymorphism and Carotid Atherosclerosis. Stroke, 1999, 30, 2180-2182.	2.0	45
350	Comparison of the Effects of Vigabatrin, Lamotrigine, and Topiramate on Quantitative EEGs in Patients with Epilepsy. Clinical Neuropharmacology, 1999, 22, 80-86.	0.7	30
351	Stroke during Sleep: Epidemiological and Clinical Features. Cerebrovascular Diseases, 1999, 9, 320-322.	1.7	38
352	Parkinson's disease: one disease entity or many?. Journal of Neural Transmission Supplementum, 1999, 56, 107-111.	0.5	12
353	Germline mutational analysis of presenilin 1 and APP genes in Jewish-Israeli individuals with familial or early-onset Alzheimer disease using denaturing gradient gel electrophoresis (DGGE). European Journal of Human Genetics, 1998, 6, 176-180.	2.8	10
354	Apolipoprotein E and Parkinson's disease. Annals of Neurology, 1998, 44, 294-294.	5.3	15
355	A statistical method for quantitative evaluation of the progression of chronic diseases: the mean score graph (MSG). , 1998, 17, 2395-2403.		2
356	Ropinirole in the treatment of early Parkinson's disease: A 6-month interim report of a 5-year levodopa-controlled study. Movement Disorders, 1998, 13, 39-45.	3.9	262
357	Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: A 6-month interim report of a 3-year study. Movement Disorders, 1998, 13, 46-51.	3.9	135
358	Dihydroergotamine Nasal Spray in the Treatment of Acute Migraine. Headache, 1998, 38, 614-617.	3.9	22
359	Effects of localized pontine lesions on auditory brain-stem evoked potentials and binaural processing in humans. Electroencephalography and Clinical Neurophysiology - Evoked Potentials, 1998, 108, 511-520.	2.0	29
360	Cerebral atherosclerosis in Parkinsonian patients. Parkinsonism and Related Disorders, 1998, 4, 87-90.	2.2	7

#	Article	IF	CITATIONS
361	Survival in Parkinson's disease: the effect of dementia. Parkinsonism and Related Disorders, 1998, 4, 179-181.	2.2	23
362	Dopamine uptake by platelet storage granules in first-degree relatives of Tourette's syndrome patients. Biological Psychiatry, 1998, 44, 1166-1170.	1.3	1
363	Disorders of excessive daytime sleepiness—an update. Journal of the Neurological Sciences, 1998, 153, 192-202.	0.6	42
364	Antineurofilament antibodies in postpolio syndrome. Neurology, 1998, 51, 1193-1195.	1.1	3
365	ACE, MTHFR, Factor V Leiden, and APOE Polymorphisms in Patients With Vascular and Alzheimer's Dementia. Stroke, 1998, 29, 1401-1404.	2.0	116
366	Lateralization and binaural discrimination of patients with pontine lesions. Journal of the Acoustical Society of America, 1998, 103, 2624-2633.	1.1	21
367	Apolipoprotein E4 in Parkinson Disease and Dementia. Alzheimer Disease and Associated Disorders, 1998, 12, 45-48.	1.3	43
368	N30 somatosensory evoked potentials in patients with unilateral Parkinson's disease. Acta Neurologica Scandinavica, 1998, 97, 73-76.	2.1	13
369	Neuroanatomical Aspects of Mydriatic Action of Morphine in Rats. Journal of Ocular Pharmacology and Therapeutics, 1997, 13, 405-413.	1.4	6
370	Saccade Characteristics in Patients with Hemispheric Stroke. Neurorehabilitation and Neural Repair, 1997, 11, 175-180.	2.9	0
371	Does Daily Aspirin Diminish Severity of First-Ever Stroke?. Archives of Neurology, 1997, 54, 1369-1371.	4.5	29
372	Evaluation of the Short Parkinson's Evaluation Scale. Clinical Neuropharmacology, 1997, 20, 322-337.	0.7	51
373	Prion diseases. Current Opinion in Neurology, 1997, 10, 273.	3.6	10
374	Risk of Dementia after a First-Ever Ischemic Stroke: A 3-Year Longitudinal Study. Cerebrovascular Diseases, 1997, 7, 48-52.	1.7	27
375	4-12-02 The presence of apolipoprotein E Ϊμ4 allele in Parkinsonian patients does not influence the development of dementia. Journal of the Neurological Sciences, 1997, 150, S226.	0.6	Ο
376	4-30-02 Movement disorders in prion diseases. Journal of the Neurological Sciences, 1997, 150, S245.	0.6	0
377	Epidemiology and inheritance of oculopharyngeal muscular dystrophy in Israel. Neuromuscular Disorders, 1997, 7, S38-S40.	0.6	46
378	Periodic lateralized epileptiform discharges (PLEDs) following stroke are associated with metabolic abnormalities. Electroencephalography and Clinical Neurophysiology, 1997, 102, 295-298.	0.3	46

#	Article	IF	CITATIONS
379	Sequential serum creatine kinase determination differentiates vaso-vagal syncope from generalized tonic-clonic seizures. Acta Neurologica Scandinavica, 1997, 95, 137-139.	2.1	27
380	Pure congenital Foixâ€Chavanyâ€Marie syndrome. Developmental Medicine and Child Neurology, 1997, 39, 696-698.	2.1	7
381	Neurological dysfunction and hyperactive behavior associated with antiphospholipid antibodies. A mouse model Journal of Clinical Investigation, 1997, 100, 613-619.	8.2	108
382	M1 Agonists for the Treatment of Alzheimer's Disease Annals of the New York Academy of Sciences, 1996, 777, 189-196.	3.8	64
383	Changes in expression of lymphocyte amyloid precursor protein mRNA isoforms in normal aging and Alzheimer's disease. Molecular Brain Research, 1996, 35, 260-268.	2.3	13
384	High blood pressure and dementia. Lancet, The, 1996, 348, 65.	13.7	2
385	APOE-??4 in Patients with Alzheimer Disease and Vascular Dementia. Alzheimer Disease and Associated Disorders, 1996, 10, 189-191.	1.3	47
386	Electroencephalographic Findings with Low-Dose Clozapine Treatment in Psychotic Parkinsonian Patients. Clinical Neuropharmacology, 1996, 19, 81-86.	0.7	19
387	Pruritus in Creutzfeldt-Jakob disease. Neurology, 1996, 46, 940-941.	1.1	17
388	A novel mutation of presenilin 1 in familial Alzheimer's disease in Israel detected by denaturing gradient gel electrophoresis. Human Genetics, 1996, 98, 700-702.	3.8	23
389	Esophageal smooth muscle dysfunction in oculopharyngeal muscular dystrophy. Digestive Diseases and Sciences, 1996, 41, 1350-1354.	2.3	17
390	Cognitive effects of scopolamine in dementia. Journal of Neural Transmission, 1996, 103, 873-881.	2.8	11
391	Plasmapheresis in Guillainâ€Barré syndrome. European Journal of Neurology, 1996, 3, 417-423.	3.3	1
392	APOEâ€Îµ4 in ageâ€related memory complaints and Alzheimer's disease. European Journal of Neurology, 1996, 3, 515-518.	3.3	4
393	Letters to the editor. Movement Disorders, 1996, 11, 115-116.	3.9	19
394	The electroencephalogram in acetazolamide-responsive periodic ataxia. Movement Disorders, 1996, 11, 283-288.	3.9	42
395	Painful calf, moving foot. Movement Disorders, 1996, 11, 339-340.	3.9	18
396	Deprenyl in Parkinson's disease. Annals of Neurology, 1996, 40, 268-269.	5.3	0

#	Article	IF	CITATIONS
397	Safety profile of copolymer 1: Analysis of cumulative experience in the United States and Israel. Journal of Neurology, 1996, 243, S23-S26.	3.6	32
398	Double-blind comparison of cabergoline and bromocriptine in Parkinson's disease patients with motor fluctuations. Neurology, 1996, 47, 785-788.	1.1	78
399	Mechanical ventilation in stroke patientsis it worthwhile?. Neurology, 1996, 47, 657-659.	1.1	49
400	Fatal insomnia in a case of familial Creutzfeldt-Jakob disease with the codon 200 <sup>Lys</sup> mutation. Neurology, 1996, 46, 758-761.	1.1	62
401	The Tel Aviv Stroke Registry. Stroke, 1996, 27, 1770-1773.	2.0	70
402	Acute Infection as a Risk Factor for Ischemic Stroke. Stroke, 1996, 27, 2204-2206.	2.0	116
403	Do Silent Brain Infarctions Predict the Development of Dementia After First Ischemic Stroke?. Stroke, 1996, 27, 904-905.	2.0	48
404	Long-term tolerability and efficacy of cabergoline, a new long-acting dopamine agonist, in Parkinson's disease. Movement Disorders, 1995, 10, 604-607.	3.9	16
405	Phenotypic heterogeneity in familial inclusion body myopathy. Muscle and Nerve, 1995, 18, 546-548.	2.2	10
406	Intravascular Malignant Lymphomatosis: A Cause of Subacute Dementia. Dementia and Geriatric Cognitive Disorders, 1995, 6, 286-293.	1.5	13
407	The oculopharyngeal muscular dystrophy locus maps to the region of the cardiac α and β myosin heavy chain genes on chromosome 14q11.2Ⱂq13. Human Molecular Genetics, 1995, 4, 429-434.	2.9	152
408	Kinematic properties of upper limb trajectories in idiopathic torsion dystonia Journal of Neurology, Neurosurgery and Psychiatry, 1995, 58, 312-319.	1.9	57
409	Parkinsonism in Patients with Lacunar Infarcts of the Basal Ganglia. European Neurology, 1995, 35, 46-49.	1.4	50
410	Low-dose Clozapine in the Treatment of Levodopa-Induced Mental Disturbances in Parkinson's Disease. Neurology, 1995, 45, 432-434.	1.1	81
411	Apolipoprotein E4 in Parkinson's disease. Neurology, 1995, 45, 1025.	1.1	1
412	Painful paroxysmal dystonia associated with focal epileptic activity Journal of Neurology, Neurosurgery and Psychiatry, 1995, 58, 257-258.	1.9	0
413	Duration and factors affecting electroencephalogram slowing after generalized tonic-clonic seizures. Journal of Epilepsy, 1995, 8, 193-196.	0.4	0
414	Decreased dopamine uptake into platelet storage granules in Gilles de la Tourette disease. Biological Psychiatry, 1995, 38, 112-115.	1.3	7

#	Article	IF	CITATIONS
415	The sympathetic skin response in reflex sympathetic dystrophy. Journal of the Neurological Sciences, 1995, 128, 92-95.	0.6	14
416	Brainstem lesions and click lateralization in patients with multiple sclerosis. Hearing Research, 1995, 82, 109-124.	2.0	43
417	Familial Alzheimer's disease associated with S182 codon 286 mutation. Lancet, The, 1995, 346, 1040.	13.7	22
418	Tests of autonomic dysfunction in patients with multiple sclerosis. Acta Neurologica Scandinavica, 1995, 92, 356-360.	2.1	27
419	Creutzfeldt-Jakob Disease (CJD) is Not an Infectious Disease. Advances in Behavioral Biology, 1995, , 87-93.	0.2	Ο
420	Natural Course of Idiopathic Torsion Dystonia among Jews. Neuroepidemiology, 1994, 13, 195-201.	2.3	7
421	Persistent hemiballism in Parkinson's disease Journal of Neurology, Neurosurgery and Psychiatry, 1994, 57, 1013-1014.	1.9	19
422	EEG Frequency Analysis in Demented and Nondemented Parkinsonian Patients. Dementia and Geriatric Cognitive Disorders, 1994, 5, 23-28.	1.5	47
423	Failure of aspirin treatment after stroke Stroke, 1994, 25, 275-277.	2.0	74
424	Saccadic responses in patients with hemispheric stroke. Documenta Ophthalmologica, 1994, 85, 267-274.	2.2	1
425	Tolerance to the mydriatic effect of buprenorphine, butorphanol, nalbuphine, and cyclorphan, and cross-tolerance to morphine in mice. Journal of Anesthesia, 1994, 8, 297-300.	1.7	1
426	Parkinsonism in adult-onset GM2 gangliosidosis. Movement Disorders, 1994, 9, 375-377.	3.9	36
427	Familial levodopa-responsive parkinsonian-pyramidal syndrome. Movement Disorders, 1994, 9, 673-675.	3.9	32
428	Magnetic resonance imaging in cerebrotendinous xanthomatosis: A prospective clinical and neuroradiological study. Journal of the Neurological Sciences, 1994, 122, 102-108.	0.6	60
429	Should sleep EEG record always be performed after sleep deprivation?. Electroencephalography and Clinical Neurophysiology, 1994, 90, 313-315.	0.3	36
430	Effects of a single intravenous dose of scopolamine on the quantitative EEG in Alzheimer's disease patients and age-matched controls. Electroencephalography and Clinical Neurophysiology, 1994, 91, 407-412.	0.3	34
431	Neurologic genetic diseases of Jewish people. Biomedicine and Pharmacotherapy, 1994, 48, 391-397.	5.6	10
432	Stress and epilepsy: the Gulf war experience. Seizure: the Journal of the British Epilepsy Association, 1994, 3, 135-139.	2.0	62

#	Article	IF	CITATIONS
433	Beneficial Effect of Cabergoline, New Long-Lasting D2 Agonist in the Treatment of Parkinson's Disease. Clinical Neuropharmacology, 1994, 17, 286-293.	0.7	16
434	Basal Ganglia Lacunes and Parkinsonism. Neuroepidemiology, 1994, 13, 108-112.	2.3	45
435	Interrater agreement in evaluation of stroke patients with the unified neurological stroke scale Stroke, 1994, 25, 1263-1264.	2.0	9
436	EEG as predictor of dementia following first ischemic stroke. Acta Neurologica Scandinavica, 1994, 90, 263-265.	2.1	26
437	THE VESTIBULO-OCULAR REFLEX AND DYSEQUILIBRIUM AFTER HEMISPHERIC STROKE1. American Journal of Physical Medicine and Rehabilitation, 1994, 73, 36-39.	1.4	2
438	Laterality of onset in idiopathic torsion dystonia. Movement Disorders, 1993, 8, 327-330.	3.9	9
439	Clinical features of oculopharyngeal muscular dystrophy among Bukhara Jews. Neuromuscular Disorders, 1993, 3, 575-577.	0.6	44
440	Increased Thromboxane B2Generation and $\hat{l}^2$ -Thromboglobulin Release from Activated Platelets in Myotonic Dystrophy. Platelets, 1993, 4, 45-48.	2.3	1
441	Clinical heterogeneity and unusual presentations of Creutzfeldt-Jakob disease in Jewish patients with the PRNP codon 200 mutation Journal of Neurology, Neurosurgery and Psychiatry, 1993, 56, 1109-1112.	1.9	64
442	Transient musical hallucinosis Journal of Neurology, Neurosurgery and Psychiatry, 1993, 56, 833-833.	1.9	19
443	Hypersensitivity Vasculitis and Systemic Lupus Erythematosus Induced by Anticonvulsants. Clinical Neuropharmacology, 1993, 16, 19-29.	0.7	57
444	Parkinson's and Alzheimer's Diseases: Epidemiological Comparison. Neuroepidemiology, 1993, 12, 336-344.	2.3	16
445	Transdermal physostigmine-absence of effect on topographic brain mapping. Behavioural Neurology, 1993, 6, 33-5.	2.1	1
446	Evaluation of the Hachinski Ischemic Scale in a Prospective Study. Dementia and Geriatric Cognitive Disorders, 1992, 3, 10-14.	1.5	1
447	The Lupus Anticoagulant and Dementia in Non-SLE Patients. Dementia and Geriatric Cognitive Disorders, 1992, 3, 140-145.	1.5	6
448	DSM-III Criteria for Primary Degenerative Dementia and Multi-Infarct Dementia. Alzheimer Disease and Associated Disorders, 1992, 6, 111-118.	1.3	13
449	Improvement of parkinsonian features correlate with high plasma levodopa values after broad bean (Vicia faba) consumption Journal of Neurology, Neurosurgery and Psychiatry, 1992, 55, 725-727.	1.9	76
450	Decreased (3H) quinuclidinyl benzilate binding to lymphocytes in Gilles de la Tourette syndrome. Biological Psychiatry, 1992, 31, 889-895.	1.3	14

#	Article	IF	CITATIONS
451	Timing and sequencing of human arm trajectories: Normal and abnormal motor behaviour. Human Movement Science, 1992, 11, 83-100.	1.4	23
452	Kinematic analysis of upper limb trajectories in Parkinson's disease. Experimental Neurology, 1992, 118, 215-226.	4.1	124
453	Absence of prion protein mutation in bipolar manic–depressive patients. British Journal of Psychiatry, 1992, 161, 132-132.	2.8	1
454	Topographic distribution of the periodic discharges in Creutzfeldt-Jakob disease (CJD). Brain Topography, 1992, 4, 201-206.	1.8	23
455	Pupillary responses and blink reflex in myotonic dystrophy. Clinical Autonomic Research, 1992, 2, 17-19.	2.5	1
456	Efficacy of memantine, an NMDA receptor antagonist, in the treatment of Parkinson's disease. Journal of Neural Transmission Parkinson's Disease and Dementia Section, 1992, 4, 277-282.	1.2	128
457	Action of opioid agonist-antagonist drugs on the pupil and nociceptive responses in mice. Journal of Anesthesia, 1992, 6, 439-445.	1.7	5
458	Naproxen Sodium Versus Ergotamine Tartrate in the Treatment of Acute Migraine Attacks. Headache, 1992, 32, 280-282.	3.9	42
459	Demyelinating peripheral neuropathy in Creutzfeldt–Jakob disease. Muscle and Nerve, 1992, 15, 1234-1239.	2.2	70
460	Heparin in the Treatment of Acute Stroke. Neurologic Clinics, 1992, 10, 209-217.	1.8	6
461	Genetic and Environmental Factors Determining the Development of Creutzfeldt-Jakob Disease in Libyan Jews. Neuroepidemiology, 1991, 10, 228-231.	2.3	16
462	The Clinical Differential Diagnosis of Dementia: Concept and Methodology. Psychiatric Clinics of North America, 1991, 14, 237-249.	1.3	10
463	A Mutation in the Prion Protein Gene in Creutzfeldtâ€Jakob Disease in Jewish Patients of Libyan, Greek, and Tunisian Origin. Annals of the New York Academy of Sciences, 1991, 640, 171-176.	3.8	19
464	EEG and Topographic Frequency Analysis in Common and Classic Migraine. Headache, 1991, 31, 232-236.	3.9	34
465	Torsion dystonia in jews and non-jews. Annals of Neurology, 1991, 29, 340-340.	5.3	1
466	Carpal tunnel syndrome: A complication of idiopathic torsion dystonia. Movement Disorders, 1991, 6, 82-84.	3.9	5
467	Creutzfeldt-Jacob disease associated with the PRNP codon 200LYS mutation: An analysis of 45 families. European Journal of Epidemiology, 1991, 7, 477-486.	5.7	115
468	Creutzfeldt-Jakob disease among libyan jews. European Journal of Epidemiology, 1991, 7, 490-493.	5.7	23

#	Article	IF	CITATIONS
469	Effects of Atropine on Learning and Memory Functions in Dementia. Clinical Neuropharmacology, 1990, 13, 241-247.	0.7	16
470	EEG Recordings Following Intrathecal Iohexol Administration. Clinical Neuropharmacology, 1990, 13, 318-321.	0.7	2
471	Sympathomimetic amines and cardiac arrhythmias. Cardiovascular Research, 1990, 24, 754-757.	3.8	5
472	Rats immunized with cholinergic synaptosomes: A model for Lambert-Eaton syndrome. Muscle and Nerve, 1990, 13, 726-733.	2.2	5
473	Dopaminergic drugs influence the intensity of catalepsy induced by microinjections of carbachol into the reticular formation. Neuroscience Letters, 1990, 119, 245-248.	2.1	6
474	Prediction of binaural click lateralization by brainstem auditory evoked potentials. Hearing Research, 1990, 49, 347-359.	2.0	45
475	Mutation in codon 200 of scrapie amyloid precursor gene linked to Creutzfeldt-Jakob disease in Sephardic Jews of Libyan and non-Libyan origin. Lancet, The, 1990, 336, 637-638.	13.7	187
476	Spongiform encephalopathy in an Israeli born to immigrants from Libya. Lancet, The, 1990, 336, 686.	13.7	22
477	Seizures of unknown origin after the age of 50: vascular risk factors. Acta Neurologica Scandinavica, 1990, 82, 78-80.	2.1	14
478	Serial EEG Recordings following Intrathecal Metrizamide Administration. Clinical EEG (electroencephalography), 1989, 20, 202-208.	0.9	4
479	Lupus anticoagulant and late onset seizures. Acta Neurologica Scandinavica, 1989, 79, 114-118.	2.1	57
480	Cerebrovascular symptoms in thromboangiitis obliterans. Acta Neurologica Scandinavica, 1989, 80, 347-350.	2.1	11
481	Nicotine mydriasis. Drug and Alcohol Dependence, 1989, 23, 133-136.	3.2	2
482	Gilles de la Tourette syndrome: EEG and mapping. Psychiatry Research, 1989, 29, 427.	3.3	1
483	Carbamazepine-Induced Systemic Lupus Erythematosus. Clinical Neuropharmacology, 1989, 12, 115-118.	0.7	16
484	EEG in demented and non-demented parkinsonian patients. Acta Neurologica Scandinavica, 1988, 78, 1-5.	2.1	104
485	Multiple sclerosis and birth order. Acta Neurologica Scandinavica, 1988, 78, 313-317.	2.1	28
486	Antibodies to Cholinergic Neurons in Alzheimer's Disease. Journal of Neurochemistry, 1988, 51, 479-485.	3.9	52

#	Article	IF	CITATIONS
487	Increased platelet aggregation and release reaction in myotonic dystrophy. Journal of the Neurological Sciences, 1988, 84, 239-246.	0.6	5
488	Antibodies to a 200 kDa cholinergic antigen in Alzheimer's disease. Biochemical Society Transactions, 1988, 16, 855-856.	3.4	0
489	Lingual Seizures <sup>1</sup> . Epilepsia, 1988, 29, 30-33.	5.1	8
490	The Specificity of the Pupillary Actions of Morphine and Naloxone. Journal of Ocular Pharmacology and Therapeutics, 1987, 3, 17-21.	1.4	2
491	Magnetic resonance imaging (MRI) in patients with complex partial seizures and normal computerized tomography (CT) scan. Clinical Neurology and Neurosurgery, 1987, 89, 231-235.	1.4	11
492	Computed tomography brain changes in Parkinsonian dementia. Neuroradiology, 1987, 29, 535-539.	2.2	16
493	Mechanisms of syncope in glossopharyngeal neuralgia. Electroencephalography and Clinical Neurophysiology, 1986, 63, 231-235.	0.3	47
494	Unilateral thermal anaesthesia. Pain, 1986, 25, 79-82.	4.2	0
495	Progressive Dystonia and Paraparesis in Cerebral Palsy. European Neurology, 1986, 25, 148-153.	1.4	33
496	Opioid Mydriasis: Cross-Tolerance between Morphine and Enkephalins. Pharmacology, 1986, 32, 278-282.	2.2	1
497	Effect of Pilocarpine on Intraocular Pressure in Ocular Hypertensive Subjects. Ophthalmic Research, 1986, 18, 34-37.	1.9	9
498	Presenile Dementia in Israel. Archives of Neurology, 1986, 43, 26-29.	4.5	92
499	Encephalopathy Associated with Sulindac. Human Toxicology, 1986, 5, 55-55.	0.9	9
500	Effect of Pilocarpine in Ocular Hypotension. Ophthalmic Research, 1985, 17, 72-74.	1.9	0
501	Ocular Tension: Comparison between the Two Eyes. Ophthalmologica, 1985, 190, 98-101.	1.9	5
502	Non-Migrainous Headache and Transient Neurological Deficits. Headache, 1985, 25, 271-272.	3.9	4
503	Circadian Rhythm of the Pupillary Response to Morphine and to Naloxone. Chronobiology International, 1985, 2, 239-241.	2.0	6
504	Sodium channel localization in rat sciatic nerve following lead-induced demyelination. Brain Research, 1985, 359, 326-331.	2.2	18

#	Article	IF	CITATIONS
505	Cardiac denervation supersensitivity produced in guinea pigs by 6-hydroxy-dopamine. Pharmacological Research Communications, 1984, 16, 171-179.	0.2	5
506	Platelet Aggregability, Disaggregability and Serotonin Uptake in Migraine. Cephalalgia, 1984, 4, 221-225.	3.9	29
507	Patterns of daytime sleepiness in narcoleptics and normals: A pupillometric study. Electroencephalography and Clinical Neurophysiology, 1984, 57, 129-133.	0.3	25
508	Association Between Ocular Pressure and Certain Health Parameters. Ophthalmology, 1984, 91, 311-314.	5.2	119
509	Pain and hyperpathia in pontine haemorrhage. Journal of Neurology, 1983, 230, 205-208.	3.6	4
510	Hyperactivity in rats following postnatal anoxia. Behavioural Brain Research, 1983, 7, 379-382.	2.2	48
511	Somatostatin mydriasis in mice. Life Sciences, 1983, 32, 1053-1056.	4.3	4
512	The pupillary effects of oploids. Life Sciences, 1983, 33, 495-509.	4.3	96
513	EEG in Cerebrotendinous Xanthomatosis (CTX). Clinical EEG (electroencephalography), 1982, 13, 89-96.	0.9	19
514	Effect of Pilocarpine on Intraocular Pressure in Normal Humans. Ophthalmic Research, 1982, 14, 182-187.	1.9	3
515	Dopamine-β-hydroxylase (DBH) in idiopathic torsion dystonia (ITD). Journal of the Neurological Sciences, 1982, 53, 91-93.	0.6	4
516	Denervation supersensitivity in the canine heart: Catecholamine-enhanced positive chronotropy without altered arrhythmogenicity. American Heart Journal, 1982, 103, 443-445.	2.7	7
517	Antibodies to muscarinic acetylcholine receptors in myasthenia gravis. Biochemical and Biophysical Research Communications, 1982, 104, 52-57.	2.1	11
518	Central and peripheral components of morphine mydriasis in mice. Pharmacology Biochemistry and Behavior, 1982, 17, 897-899.	2.9	13
519	The effect of L-dopa on pupillary diameter in mice. Experientia, 1982, 38, 481-482.	1.2	5
520	ANTAGONISM OF OPIATE MYDRIASIS IN MICE. British Journal of Pharmacology, 1981, 73, 807-810.	5.4	7
521	Osmotic fragility of erythrocytes in myopathies. Journal of Neurology, 1981, 224, 253-255.	3.6	1
522	ACONIST INTERACTION AND DECENTRALIZATION SUPERSENSITIVITY IN THE NICTITATING MEMBRANE OF THE CAT. Clinical and Experimental Pharmacology and Physiology, 1981, 8, 11-16.	1.9	0

#	Article	IF	CITATIONS
523	Lack of effect of cannabinoids on carbonic anhydrase. Journal of Neural Transmission, 1980, 49, 205-206.	2.8	5
524	Tolerance to the mydriatic effects of morphine in mice. Journal of Neural Transmission, 1980, 48, 43-47.	2.8	7
525	Torsion dystonia in israel. Annals of Neurology, 1980, 8, 387-391.	5.3	46
526	SERUM DOPAMINE ?-HYDROXYLASE (D?H) LEVELS DURING TILTING IN PATIENTS WITH SPINAL CORD INJURIES. Clinical and Experimental Pharmacology and Physiology, 1980, 7, 367-371.	1.9	1
527	Correlation of Headache Complaints With Some Physiological Parameters in a Healthy Population. Headache, 1980, 20, 196-198.	3.9	9
528	The effect of dopamine on the pupillary diameter in mice. Life Sciences, 1980, 26, 757-763.	4.3	10
529	Enkephalin mydriasis in mice. European Journal of Pharmacology, 1980, 65, 285-287.	3.5	9
530	The ocular effects of cannabinoids. General Pharmacology, 1980, 11, 419-423.	0.7	17
531	Rostaglandins Do Not Affect Ion Concentrations in Human Erythrocytes. Archives Internationales De Physiologie Et De Biochimie, 1979, 87, 311-314.	0.2	2
532	Effect of β-Blockers on Sodium and Potassium Content of Human Erythrocytes. Archives Internationales De Physiologie Et De Biochimie, 1979, 87, 935-941.	0.2	2
533	The mechanism of imipramine in enuresis nocturna. Clinical and Experimental Pharmacology and Physiology, 1979, 6, 31-35.	1.9	10
534	Amantadine antagonism of oxotremorine effects. Journal of Neural Transmission, 1979, 46, 79-83.	2.8	8
535	Muscarinic acetylcholine receptors in cat iris. Biochemical Pharmacology, 1979, 28, 1505-1511.	4.4	17
536	Denervation, supersensitivity and muscarinic receptors in the cat iris. Biochemical Pharmacology, 1979, 28, 1513-1518.	4.4	44
537	Dopaminergic and non-dopaminergic circling activity of mice. Neuroscience, 1979, 4, 1085-1088.	2.3	14
538	Dopamine-beta-hydroxylase activity in serum of patients with hepatic damage. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 1979, 3, 551-553.	0.6	2
539	The function of presynaptic dopamine receptors on noradrenergic nerve terminals. Medical Hypotheses, 1979, 5, 1131-1132.	1.5	1
540	Morphine mydriasis in mice. Life Sciences, 1979, 24, 1667-1673.	4.3	25

#	Article	IF	CITATIONS
541	Abolition of oxotremorine effects by I-DOPA pretreatment. Neuropharmacology, 1979, 18, 601-603.	4.1	17
542	Amethocaine and Intraocular Pressure. Ophthalmic Research, 1979, 11, 212-215.	1.9	8
543	Asymmetry of turning behaviour of rats induced by amphetamine and apomorphine. Experientia, 1978, 34, 616-616.	1.2	8
544	Effect of electroconvulsive treatment on serum dopamine-beta-hydroxylase activity in man. Experientia, 1978, 34, 212-213.	1.2	2
545	The pathophysiology of dystonia. Journal of Neural Transmission, 1978, 42, 245-250.	2.8	17
546	Sex-ratio in chorea associated with systemic lupus erythematosus and hypoparathyroidism. Role of sex hormones. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 1978, 2, 579-584.	0.6	0
547	Muscle hypertrophy with neuropathy. Journal of the Neurological Sciences, 1978, 38, 399-408.	0.6	39
548	Central connections of the salivation reflex in man. Experimental Neurology, 1978, 62, 497-499.	4.1	4
549	Electroretinographic responses in lafora disease. Electroencephalography and Clinical Neurophysiology, 1978, 45, 785-788.	0.3	5
550	The stability of dopamine-β-hydroxylase activity in blood samples. Clinica Chimica Acta, 1978, 82, 291-292.	1.1	7
551	Waardenburg syndrome with a fixed dilated pupil British Journal of Ophthalmology, 1978, 62, 491-494.	3.9	11
552	Serum Dopamine Beta-Hydroxylase Activity in Acute Cardiac Disease. Chest, 1978, 74, 522-525.	0.8	3
553	Diaphragmatic Paralysis. JAMA - Journal of the American Medical Association, 1977, 238, 128.	7.4	0
554	Effects of propranolol and pindolol on platelet aggregation and serotonin release. Life Sciences, 1977, 20, 407-411.	4.3	36
555	Ventilatory response to carbon dioxide in multiple sclerosis. Journal of Neurology, 1977, 215, 67-71.	3.6	1
556	Release of platelet 5-hydroxytryptamine by plasma taken from patients during and between migraine attacks. Pain, 1976, 2, 315-318.	4.2	44
557	Transient Neurogenic Urinary Retention. European Neurology, 1976, 14, 383-385.	1.4	0
558	Convulsive Fits in Thyrotoxicosis. Epilepsia, 1976, 17, 33-34.	5.1	22

AMOS D KORCZYN

#	Article	IF	CITATIONS
559	Denervation Supersensitivity in Horner's Syndrome. Ophthalmologica, 1975, 170, 313-319.	1.9	6
560	Cholesterol and uric acid levels in patients with bell's palsy. Journal of Neurology, 1975, 208, 315-317.	3.6	1
561	Phenytoin and folate deficiency: Failure to show dose dependency. Journal of Neurology, 1974, 207, 151-153.	3.6	1
562	Bell's palsy with monoclonal gammopathy. Journal of Neurology, 1973, 203, 337-340.	3.6	0
563	Transient Bilateral Diaphragmatic Paralysis. Chest, 1973, 64, 355-357.	0.8	20
564	BELL'S PALSY AND PREGNANCY. Acta Neurologica Scandinavica, 1971, 47, 603-607.	2.1	23
565	Diaphragmatic involvement in hemiplegia and hemiparesis Journal of Neurology, Neurosurgery and Psychiatry, 1969, 32, 588-590.	1.9	23
566	Respiratory responses to brain stem stimulation. Journal of the Neurological Sciences, 1966, 3, 217-228.	0.6	3
567	Effect of brain transections on the respiratory response to nerve stimulation. Journal of the Neurological Sciences, 1965, 2, 241-252.	0.6	3
568	Effect of brain stem transections on vasomotor responses to nerve stimulation. Archives Internationales De Physiologie Et De Biochimie, 1963, 71, 662-673.	0.2	10
569	Catechol-O-methyltransferase inhibitors in the management of Parkinson's disease. , 0, , 76-82.		1
570	Sexuality and Parkinson's Disease. , 0, , 517-526.		5